Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugates
- 1 June 1994
- journal article
- research article
- Published by Elsevier in Trends in Biotechnology
- Vol. 12 (6) , 234-239
- https://doi.org/10.1016/0167-7799(94)90122-8
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: substrates for an antibody targeted enzymeThe Journal of Organic Chemistry, 1992
- Preparation and characterization of a .beta.-lactamase-Fab' conjugate for the site-specific activation of oncolytic agentsBioconjugate Chemistry, 1992
- Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugatesBioconjugate Chemistry, 1991
- Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugateAdvances in Enzyme Regulation, 1991
- Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapyThe FASEB Journal, 1990
- Mitotoxins: Growth factor-targeted cytotoxic moleculesProgress in Growth Factor Research, 1990
- The First Bagshawe lecture: Towards generating cytotoxic agents at cancer sitesBritish Journal of Cancer, 1989
- Carboxypeptidase-mediated release of methotrexate from methotrexate .alpha.-peptidesBiochemistry, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- A cytotoxic agent can be generated selectively at cancer sitesBritish Journal of Cancer, 1988